MedPath
Found 83 clinical trials|View Analysis
Sort by:

A Multicenter, Randomized Controlled Phase II Clinical Study of Standard Therapy Combined with Compound Preparation Biolosion in Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2
Not yet recruiting
Conditions
Breast Cancer
Triple Negative Breast Cancer (TNBC)
Early Stage Breast Cancer
Immunotherapy
Probiotic
First Posted Date
2025-01-10
Last Posted Date
2025-01-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
192
Registration Number
NCT06768931
Locations
🇨🇳

Sun yat sen university cancer center, Guangzhou, Guangdong, China

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3
Not yet recruiting
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Drug: AK112
Drug: Nab-paclitaxel
Drug: Placebo
First Posted Date
2025-01-10
Last Posted Date
2025-01-10
Lead Sponsor
Akeso
Target Recruit Count
416
Registration Number
NCT06767527
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Phase 2
Not yet recruiting
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Radiation: radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
Radiation: radiotherapy 5 Gy × 5 fractions, once a day
Radiation: radiotherapy 8 Gy × 5 fractions, once a day
Radiation: radiotherapy 8 Gy × 3 fractions, once every other day
Radiation: radiotherapy 10 Gy× 3 fractions, once every other day
Drug: Toripalimab
Drug: chemotherapy regimen selected by the investigator
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
60
Registration Number
NCT06735131

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3
Not yet recruiting
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Drug: ESG401
Drug: Investigator's Choice Chemotherapy
First Posted Date
2024-12-13
Last Posted Date
2024-12-13
Lead Sponsor
Shanghai Escugen Biotechnology Co., Ltd
Target Recruit Count
504
Registration Number
NCT06732323
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2
Not yet recruiting
Conditions
Triple Negative Breast Cancer (TNBC)
Metastatic Breast Cancer
Interventions
First Posted Date
2024-12-12
Last Posted Date
2024-12-12
Lead Sponsor
Fudan University
Target Recruit Count
40
Registration Number
NCT06731153
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Phase 2
Not yet recruiting
Conditions
Recurrent Platinum-resistant Epithelial Ovarian Cancer
Triple Negative Breast Cancer (TNBC)
Cervical Cancers
Small Cell Lung Cancer
Hepatocellular Carcinoma (HCC)
Colorectal Cancer
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Drug: B1962
First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
Tasly Biopharmaceuticals Co., Ltd.
Target Recruit Count
120
Registration Number
NCT06724263
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2
Recruiting
Conditions
Advanced Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer (TNBC)
HER2-negative Breast Cancer
Breast Cancer
Interventions
Drug: SHR-A1811
Drug: SHR-A1921
Drug: SHR-A2009
Drug: SHR-A2102
First Posted Date
2024-10-18
Last Posted Date
2024-12-10
Lead Sponsor
Fudan University
Target Recruit Count
120
Registration Number
NCT06649331
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial

Phase 2
Recruiting
Conditions
Triple Negative Breast Cancer (TNBC)
First Posted Date
2024-10-15
Last Posted Date
2024-12-13
Lead Sponsor
Fudan University
Target Recruit Count
129
Registration Number
NCT06636981
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Phase 3
Not yet recruiting
Conditions
Breast Cancers
Triple Negative Breast Cancer (TNBC)
Interventions
Other: Deescalation
Drug: Pembrolizumab
First Posted Date
2024-09-23
Last Posted Date
2024-09-23
Lead Sponsor
UNICANCER
Target Recruit Count
2454
Registration Number
NCT06606730

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Phase 2
Not yet recruiting
Conditions
Triple Negative Breast Cancer (TNBC)
Brain Metastasases
Interventions
Drug: JK-1201I
First Posted Date
2024-09-06
Last Posted Date
2024-09-06
Lead Sponsor
JenKem Technology Co., Ltd.
Target Recruit Count
25
Registration Number
NCT06586866
© Copyright 2025. All Rights Reserved by MedPath